<DOC>
	<DOCNO>NCT02063295</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , pharmacokinetics beloranib obese subject hypothalamic injury .</brief_summary>
	<brief_title>An Efficacy , Safety , Pharmacokinetics Study Beloranib Obese Subjects With Hypothalamic Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Craniopharyngioma</mesh_term>
	<mesh_term>Adamantinoma</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Obesity consequence acquire anatomical hypothalamic damage evidence BMI ≥30 ≤60 kg/m2 Greater 6 month posttreatment , include chemotherapy , surgery radiation result injury hypothalamus and/or pituitary Stable body weight least 3 month Type 2 diabetes mellitus allow Males take gonadotropin replacement therapy ( LH/FSH ) Subjects plan fertility treatment within 6 month study participation Use weight loss agent , include herbal medication , past 3 month Current anticipate chronic use narcotic opiates History severe psychiatric disorder Type 1 diabetes mellitus Metabolic disorder genetic disorder link obesity History bariatric surgery Participation clinical study investigational drug device within 3 month prior enrollment study Blood loss donation &gt; 500 mL within past 3 month Females pregnant , nursing , intend become pregnant study male plan father/conceive child within 6 month completion study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Beloranib</keyword>
	<keyword>ZGN-440</keyword>
	<keyword>ZGN-440 injectable suspension</keyword>
	<keyword>ZGN-433</keyword>
</DOC>